Industry Satellite Symposia
ASTRO has reviewed and approved these symposia for presentation. These symposia represent the content and views of the supporters and are not part of the official ASTRO Annual Meeting.
Sunday, October 24
6:30 p.m. - 8:00 p.m. | Implementing Synergistic Multimodal Approaches With Tumor Treating Fields to Extend Survival in Aggressive Cancers
Hyatt Regency McCormick Place, Regency Ballroom A
Dinner will be provided starting at 6:00 p.m.
For more information or to register for our live symposium in Chicago please visit www.peerview.com/Chicago21-Live
Not going to Chicago? Tune in to our live web broadcast instead! For more information or to register for our live web broadcast please visit www.peerview.com/Chicago21-Virtual
This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Medical Learning Institute Inc. Medical Learning Institute Inc., is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed with our educational partner, PVI, PeerView Institute for Medical Education.
Medical Learning Institute Inc., designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been designed to meet the educational needs of radiation oncologists, medical oncologists, and other health care professionals involved in the care of patients with solid tumors.
- Describe the mechanistic rationale and clinical evidence for validated locoregional therapies, such as tumor treating fields (TTFields), for glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM)
- Appraise new clinical evidence on investigational multimodal strategies with synergistic mechanisms of action (e.g., TTFields in combination with systemic therapy, radiotherapy or other modalities) across a range of solid tumor types, including lung, pancreatic, gastric, liver and ovarian cancers
- Integrate novel locoregional therapies into the therapeutic management of appropriately selected patients with GBM, MPM or other solid tumors, including via clinical trial enrollment
- Implement team-based strategies to minimize and manage adverse events associated with novel therapeutic modalities in patients with solid tumors
This activity is supported by an educational grant from Novocure.
Monday, October 25
6:30 p.m. - 8:30 p.m. | Next Generation PSMA-targeted PET Imaging in the Detection of Prostate Cancer and Impact on Patient Management
Hyatt Regency McCormick Place, Regency Ballroom AB
Dinner will be provided
This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Haymarket Medical Education. Haymarket Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
In support of improving patient care, Haymarket Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.
Haymarket Medical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits
™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is awarded 1.5 contact hours.
Radiation oncology professionals including physicians, nurses, biologist, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies.
RSVP ONLINE: www.mycme.com/PSMA_TargetedProstateCancer
TOLL FREE: (877) 210-5355
Participants With Special Needs:
- Describe how emerging next-generation imaging (NGI) can help attain the goals of improving early detection of prostate cancer
- Explain the mechanism of uptake for radiotracers of a major class of NGI: prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET)
- Evaluate the evidence base for PSMA PET/computed tomography (PSMA PET/CT), including key clinical trials of gallium-68 (68Ga) and fluorine-18 (18F) modalities
- Consider criteria for the selection of PSMA PET/CT modalities, such as image quality, radiation dosimetry, lesion uptake, rate of urinary excretion and adverse events
If you require any special dietary or ADA accommodations, please contact Christie Kavanagh at 1-800-379-6048, ext. 4893.
This activity is supported through an educational grant from Lantheus Medical Imaging, Inc.